February 5, 2024 10:58 AM EST
News Briefing

No­var­tis re­port­ed­ly in talks to buy Mor­phoSys; Astel­las cuts PhII pro­gram; Si­lence's $120M pri­vate place­ment

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Plus, news about Ad­verum, Bridge­Bio Phar­ma, Vax­cyte, Cor­bus and Im­muno­core:

No­var­tis re­port­ed­ly in deal talks with Mor­phoSys: The Swiss Big Phar­ma is in ad­vanced talks …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times